Anticoccidial Drugs Market Size (2021 to 2030)

The global anticoccidial drugs market is expected to have a growth rate of 3.61% CAGR from 2021 to 2030. As a result, the market is anticipated to grow by USD 1691.94 Million by 2028.

Anticoccidial Drugs Market Share Insights:

Based on the Drug type, the ionophore anticoccidials segment had the largest market share of the global anticoccidial drugs market in 2022. Based on animal type, the poultry animal segment had the largest market share of the global anticoccidial drugs market in 2022. The North American anticoccidial drugs market had the most significant global market share in 2022.

Anticoccidial drugs are a part of the veterinary medicine industry. These drugs are used to prevent and treat coccidiosis in animals. When animals are diagnosed with coccidiosis, they suffer from diarrhea, weight loss, and reduced growth and productivity. Coccidiosis can also result in death in some cases. Coccidiosis majorly impacts the intestines of animals. This parasitic disease is infectious. To treat coccidiosis, anticoccidial drugs are used in the treatment procedures to remove the parasites. Anticoccidial drugs are of two types, which are ionophores and chemical anticoccidials. Monensin and salinomycin are ionophores, and sulfonamides and nitroimidazoles are chemical anticoccidials. As said earlier, these drugs are primarily used to control the spread of coccidiosis; however, the consumption of the drugs has to be according to the saying of veterinarians, and overuse of these drugs could result in other animal problems.

Impact of COVID-19 on the global anticoccidial drugs market:

The disease has spread to almost every country globally since the COVID-19 virus outbreak in December 2019, prompting the World Health Organization to declare it a public health emergency. Coccidiosis is a viral disease caused by a single-cell parasite that can only be seen under a microscope. It affects the intestinal tracts of animals. Weight loss, moderate sporadic to extreme diarrhea, diarrhea containing blood or mucus, dehydration, and decreased breeding are all signs of coccidiosis, one of the most common parasitic diseases in domesticated animals. Growing clinical trials in developing medicines or vaccines for animals to prevent infections propels this market's growth rate to new heights. Anticoccidial drugs are drug preparations used to treat coccidiosis in animals. These are given to animals and birds to stop coccidia from reproducing and destroying protozoa in the intestine. In some countries, the transmission of coronavirus from humans to animals boosts the market's growth rate during these pandemic times.

MARKET DRIVERS:

YOY growth in the prevalence of coccidiosis and increasing focus on animal health primarily accelerates the global anticoccidial drugs market. Anticoccidial drugs are the agents used to treat, prevent, and control coccidial infections. However, there is a risk of increased coccidiosis due to environmental factors and others, such as contamination or other issues related to hygienic measures. Hence, there is an alarming demand for newer anticoccidial drugs in the drug market. Increasing the need to prevent the spread of diseases in animals with effective medication and the rise in the consumption rate of meat and poultry products are the primary reasons driving the growth of the global anticoccidial drugs market.

The growing number of veterinary hospitals, rise in demand to improve the quality of drugs with different techniques, growing disposable income in urban areas, and people's concern towards maintaining a healthy diet are further helping the global anticoccidial drugs market to grow. According to the data published by the American Veterinary Medical Association (AVMA), an estimated 20,000 veterinary clinics, hospitals, and 90,000 veterinary practitioners were there in the United States in 2021.

Additionally, growing support from the government through investments, the rising demand to increase the production rate of drugs with high quality, and increasing concern towards animals' health conditions further accelerate market growth. For instance, the United States Department of Agriculture (USDA) invested an amount of USD 19 million in conducting R&D for animal health and animal diseases to prevent, control, and treat various diseases in livestock and poultry and also to innovate new veterinary medical equipment, diagnostic tools, and treatment procedures via NIFA in 2019.

Likewise, the Australian government announced an investment of USD 100 million for veterinary healthcare, primarily to conduct R&D to develop advanced medical devices, drugs, and treatment procedures for various animal diseases in 2020. Furthermore, the adoption of the latest technology, the launch of valuable products, and the rising number of infectious diseases among animals and birds are expected to fuel the growth opportunities for the global anticoccidial drugs market.